IL295014A - Preparations for the treatment of angiolipoma - Google Patents
Preparations for the treatment of angiolipomaInfo
- Publication number
- IL295014A IL295014A IL295014A IL29501422A IL295014A IL 295014 A IL295014 A IL 295014A IL 295014 A IL295014 A IL 295014A IL 29501422 A IL29501422 A IL 29501422A IL 295014 A IL295014 A IL 295014A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- angiolipoma
- nrnr12
- halogen
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dental Preparations (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Prostheses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966577P | 2020-01-28 | 2020-01-28 | |
| PCT/IB2021/000035 WO2021152390A1 (en) | 2020-01-28 | 2021-01-27 | Compositions for the treatment of angiolipoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295014A true IL295014A (en) | 2022-09-01 |
Family
ID=77078612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295014A IL295014A (en) | 2020-01-28 | 2021-01-27 | Preparations for the treatment of angiolipoma |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230089484A1 (https=) |
| EP (1) | EP4096653A4 (https=) |
| JP (1) | JP7850665B2 (https=) |
| CN (1) | CN115335047B (https=) |
| AU (1) | AU2021213469A1 (https=) |
| IL (1) | IL295014A (https=) |
| WO (1) | WO2021152390A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307323B1 (en) | 2015-06-15 | 2022-07-13 | Raziel Therapeutics Ltd. | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
| AU2020347539A1 (en) * | 2019-09-15 | 2022-03-31 | Raziel Therapeutics Ltd. | Compositions for the treatment of solid tumors |
| JP2024529906A (ja) * | 2021-07-28 | 2024-08-14 | ラジエル セラピューティクス エルティーディー． | 脂肪腫の疼痛を処置するための組成物および方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102712601A (zh) * | 2009-11-12 | 2012-10-03 | 赛尔维他股份公司 | 化合物、其制备方法、药物组合物、化合物的用途、用于调节或调控丝氨酸/苏氨酸激酶的方法以及丝氨酸/苏氨酸激酶调节剂 |
| KR101986272B1 (ko) * | 2011-11-15 | 2019-06-05 | 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도 |
| RU2020111934A (ru) * | 2013-10-08 | 2020-04-29 | Промедиор, Инк. | Способы лечения фиброзного рака |
| EP3060215A4 (en) * | 2013-10-21 | 2017-06-14 | Alevere Medical Corporation | Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof |
| WO2016020919A1 (en) * | 2014-08-07 | 2016-02-11 | Raziel Therapeutics Ltd. | Compositions comprising tricyclic compounds, and uses thereof |
| EP3307323B1 (en) | 2015-06-15 | 2022-07-13 | Raziel Therapeutics Ltd. | Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof |
-
2021
- 2021-01-27 US US17/795,204 patent/US20230089484A1/en active Pending
- 2021-01-27 EP EP21748312.2A patent/EP4096653A4/en active Pending
- 2021-01-27 WO PCT/IB2021/000035 patent/WO2021152390A1/en not_active Ceased
- 2021-01-27 IL IL295014A patent/IL295014A/en unknown
- 2021-01-27 CN CN202180025551.1A patent/CN115335047B/zh active Active
- 2021-01-27 JP JP2022542777A patent/JP7850665B2/ja active Active
- 2021-01-27 AU AU2021213469A patent/AU2021213469A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4096653A4 (en) | 2024-02-28 |
| EP4096653A1 (en) | 2022-12-07 |
| JP7850665B2 (ja) | 2026-04-23 |
| WO2021152390A1 (en) | 2021-08-05 |
| US20230089484A1 (en) | 2023-03-23 |
| JP2023510865A (ja) | 2023-03-15 |
| CN115335047B (zh) | 2025-09-19 |
| CN115335047A (zh) | 2022-11-11 |
| AU2021213469A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL295014A (en) | Preparations for the treatment of angiolipoma | |
| AU2017274521B2 (en) | Method of treating liver fibrosis | |
| JP7822308B2 (ja) | 固形腫瘍の処置のための組成物 | |
| KR101249707B1 (ko) | 투석액 및 이에 관련된 방법과 시스템 | |
| TW202432558A (zh) | 一種噠嗪稠芳環化合物及其用途 | |
| KR19980081621A (ko) | 과민성 장 증후군의 증상을 치료하기 위한 엔케이-1 수용체 길항물질 | |
| US20180318304A1 (en) | Methods of Using BTK Inhibitors to Treat Dermatoses | |
| IL301325A (en) | Compositions and methods for the treatment of lipid-related disorders | |
| CN116261561B (zh) | 某些化学组合物及其使用方法 | |
| WO2022058792A1 (en) | Compositions for the treatment of fat related conditions and disorders | |
| US20240335424A1 (en) | Compositions and methods for treating lipoma pain | |
| HK40077772A (en) | Compositions for the treatment of solid tumors | |
| AU2004226547B2 (en) | T-Type calcium channel blockers | |
| CN113164487B (zh) | 磷酸二酯酶抑制剂 | |
| WO1994018974A1 (en) | (+)- 2-methylpiperidine as modulator of cholinergic systems |